spec sheet11 rows
Bronchogen is a synthetic tetrapeptide from the Khavinson family of tissue-specific peptide bioregulators, built from the amino acid composition of a bronchial mucosa polypeptide complex and aimed at the bronchopulmonary system [3][10]. It is normally written Ala-Glu-Asp-Leu, and it is not Chonluten, which is the tripeptide Glu-Asp-Gly drawn from the same complex. The research file is coherent and entirely preclinical; seventeen papers, no human study of any design, and no independent replication of the respiratory claim outside the originating research network.
- Rebuilt damaged airway lining in rat models
- Restored the lung's ciliated sweeping cells
- Lifted secretory IgA and surfactant protein B
- Quieted inflammatory cell traffic in the airways
- Shifted bronchial identity genes in human cultures
- DNA binding proven by four physical methods
- Unknown in humans; nothing has been systematically looked for
- The clearest cell-culture effect is increased proliferation in aged bronchial cultures, and no study has examined what that means in a living airway [8]
Overview
Bronchogen is a synthetic short peptide bioregulator with the amino acid sequence Ala-Glu-Asp-Leu (AEDL), a tetrapeptide belonging to the family of tissue-specific short peptides developed by the St. Petersburg Institute of Bioregulation and Gerontology and associated with the work of Vladimir Khavinson [2][5]. It is the synthetic analogue of a bronchopulmonary peptide preparation and is designed to act selectively on the tissues of the bronchi and lungs [1][2].
The compound is part of a broader class of short peptides, generally two to seven amino acids in length, that are studied as regulators of gene expression and cell differentiation. These peptides are notable for their small size, which allows them to penetrate the cell membrane and even enter the nucleus, where they can interact with DNA and histone proteins [3][5]. Bronchogen specifically has been shown to enter cells and bind DNA in a sequence-selective manner, preferring CTG-containing sequences that are targets for cytosine methylation [3].
Research applications for Bronchogen center on respiratory and bronchopulmonary support, cellular regeneration, and geroprotection, meaning the slowing of age-related cellular decline in target tissues [1][2]. Within experimental models it is used to study tissue-specific differentiation and epigenetic peptide signaling [4][5]. Regulatory status places it among the peptide bioregulators marketed in Russia as preparations or supplements; it is not an approved pharmaceutical in Western countries and is handled as a research peptide, typically supplied as a lyophilized powder or in capsule form.
- Bronchogen is only four amino acids long, small enough to slip through the cell membrane and reach the nucleus, where it is proposed to bind DNA and influence which genes are switched on.
- In laboratory studies the peptide's differentiation-promoting effect was stronger in older, late-passage cell cultures than in young ones, the opposite of what many agents show.
Mechanism
The claim is that Bronchogen crosses the cell and nuclear membranes without a receptor, binds DNA and histone tails, and switches on the transcription programme that keeps bronchial epithelium differentiated [3][8]. The binding half of that is the strongest part of the file and it is measured rather than asserted: differential scanning calorimetry put the melting temperature of calf thymus and mouse liver DNA up by 3.1 degrees C [11], spectrophotometry, viscometry and circular dichroism located the interaction in the major groove at N7 guanine [8], and fluorescence quenching reported a preference for CTG-containing sequences [3]. In H1-depleted rat liver chromatin the unfolded the nucleosome core and released about 15 percent of core DNA [12].
⚠️ Binding DNA is not the same as regulating a gene, and the literature contradicts itself on the step between them. The calorimetry paper states plainly that the is neither AT-specific nor GC-specific and describes the binding as strong and occasional [11], which sits badly against a mechanism that needs sequence specificity to explain tissue specificity. The methylation study is the honest one: promoter methylation of NKX2-1 and SCGB1A1 moved with expression, while FOXA1, FOXA2, SCGB3A2 and SFTPA1 changed expression with no methylation change at all, and the authors say those must be controlled by something else [9].
⚠️ Tissue specificity is the premise of the whole bioregulator family and this compound is the case against it. The same binds wheat histones [4], reorganises rat liver chromatin [12], stimulates callus growth and leaf formation in tobacco [15], elongates tobacco roots under salt stress [16], raises glutathione in tobacco by more than threefold [17] and activates in tobacco root meristem [18]. A molecule that does all of that is not obviously acting on bronchial epithelium because it recognises bronchial epithelium.
How it would reach a cell is unresolved. A docking study scored it among the more efficient ligands of the LAT1, LAT2 and PEPT1 transporters, but that study modelled 26 peptides and measured no transport [14]; a second docking paper placed AEDL and EDL at a ctcc sequence [13]. Both are predictions.
receptor fingerprint
DNA, major groove at N7 guaninedirect binding, measured by calorimetry, spectrophotometry, viscometry and circular dichroism
NKX2-1 (TTF-1)expression change accompanied by a correlated promoter methylation change in bronchial cells
SCGB1A1 (club cell secretory protein)expression change with a correlated methylation change
Nucleosome core and histonesunfolds the nucleosome core in H1-depleted chromatin; binds histones H1, H2B, H3 and H4, though the histones tested were from wheat
FOXA1 / FOXA2expression changed with no accompanying methylation change, so the mechanism is unexplained
Ki67 and Mcl-1raised in bronchial epithelial cultures, most strongly in the oldest passages
Secretory IgA and surfactant protein Braised in bronchoalveolar lavage in a rat COPD model
LAT1 / LAT2 / PEPT1 transportersfavourable docking scores only; no transport was measured
Safetyrisks and cautions, not medical advice
HUMAN SAFETY DATA: none. No trial, no case series, no pharmacovigilance record, and no registered study anywhere in ClinicalTrials.gov. That is absence of investigation rather than evidence of safety, and the distinction matters more here than usual because nothing is known about what happens to the peptide after administration either; there is no absorption, distribution, metabolism or clearance data in any species.
One specific caution follows from the data rather than from generic hedging. The strongest cell-culture finding is that the peptide raised the proliferation markers Ki67 and Mcl-1 most in the OLDEST bronchial cultures tested [8]. Pushing proliferation in airway epithelium is not self-evidently harmless, and no study in the file has asked that question in a mammal, let alone in a person.
In the rat COPD work a month of dosing was reported without adverse findings [6][7], which is the only tolerability signal that exists and comes from one laboratory in one species.
Reconstitutionarithmetic only, not dosing advice
arithmetic only; not medical or dosing advice.
History
Bronchogen belongs to the peptide bioregulator programme founded by Vladimir Khavinson and Vyacheslav Morozov, dating from 1973. The method was to extract a polypeptide complex from an animal organ, determine its amino acid composition, then synthesise a short peptide representing that complex; Bronchogen is the bronchial mucosa member of that family, and Chonluten is a second, shorter peptide drawn from the same complex. The institutional home is the St Petersburg Institute of Bioregulation and Gerontology, with the Pavlov Institute of Physiology and Mechnikov North-Western State Medical University recurring as co-affiliations; the rat COPD work comes from the Research Institute of Pulmonology at Pavlov First St Petersburg State Medical University, and the plant work from an agricultural biotechnology institute in Moscow that has collaborated with the same group for over a decade.
⚠️ The sequence is not fully settled, and both forms are in print from the same network. Ala-Glu-Asp-Leu is dominant and more recent [3][9][13][15]. Ala-Asp-Glu-Leu appears in the most-cited mechanistic paper on the compound [8] and in the calorimetry work [11][12]. The composition is agreed; the order of the glutamate and the aspartate is not.
Regulatory status: not an approved drug in any Western market, and no registered clinical trial of it exists. Material sold under this name is an unregulated research chemical.
Reputation
Within the peptide bioregulator community bronchogen is valued as a targeted, respiratory-focused member of a family that has attracted genuine scientific curiosity for its epigenetic mode of action. Laboratory work is intriguing; in cultured human bronchial cells the peptide stimulated markers of healthy differentiation, and the effect was reportedly more pronounced in aged cultures, which is the basis for its geroprotective framing. It is honest to note that this evidence remains largely confined to cell and molecular models, with little in the way of large human trials. Enthusiasts appreciate its precise, tissue-directed concept, while recognizing that its promise for respiratory resilience is still being explored rather than firmly established.
Where to buy
1 other outlet
Suppliers
Vendors carrying Bronchogen, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
Kimera Chems
Brochogen
RUO
Bronchogen
Research
- 2006first cited[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues cu…
- 2011most active year3 papers
- 2025most recentPeptide AEDL Activates Metabolism and Autophagy in Root Cells of Nicotiana tabacum.
- 1.Peptides tissue-specifically stimulate cell differentiation during their aging
- 2.Peptide Regulation of Cell Differentiation
- 3.Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
- 4.Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides
- 5.Peptide Regulation of Gene Expression: A Systematic Review
- 6.Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.
- 7.[ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY].
- 8.Peptide regulation of gene expression and protein synthesis in bronchial epithelium.
- 9.Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells.
- 10.[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].
- 11.Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability.
- 12.Influence of tetrapeptide on chromatin thermostability.
18 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Which of these findings are human and which are animal?
The whole-animal work is rat, in one COPD model from one laboratory. The gene expression and DNA binding work is human cell culture and test tube chemistry. Nothing has been tested in a living person, so no human dose or effect size exists.
How is Bronchogen different from Chonluten?
Different molecules of different lengths. Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu; Chonluten is the tripeptide Glu-Asp-Gly. Both were derived from the same bronchial mucosa complex, which is why they are so often mixed up.
Why do some sources spell it Brochogen?
That spelling comes from vendor listings and returns nothing in the research literature. Bronchogen is the form used in every published paper, and it is also what the same vendors use in their own product descriptions.
Is the sequence settled?
The four amino acids are agreed. The order of the glutamate and the aspartate is not; both Ala-Glu-Asp-Leu and Ala-Asp-Glu-Leu appear in papers from the same research network.
Limitations of the evidence
- No human study of any design exists, and no clinical trial of it has ever been registered
- The one whole-animal disease result comes from a single laboratory and was published twice; it has never been independently reproduced [6][7]
- DNA binding was found to be neither AT-specific nor GC-specific, which undercuts the sequence specificity the mechanism needs [11]
- Several genes changed expression with no change in promoter methylation, so the proposed epigenetic route does not explain its own results [9]
- The same peptide is active in tobacco roots and on wheat histones, which is hard to square with a tissue-specific agent [4][15][16][17][18]
- No pharmacokinetics in any species; the transporter story is docking scores with no transport measured [14]
- The published sequence disagrees with itself between AEDL and ADEL [8][11]
Adverse effects
- Unknown in humans; nothing has been systematically looked for
- The clearest cell-culture effect is increased proliferation in aged bronchial cultures, and no study has examined what that means in a living airway [8]
Notes and cautions
- Not Chonluten. That is the tripeptide Glu-Asp-Gly from the same bronchial complex and it has its own entry; the two are routinely conflated
- One residue away from Epitalon (Ala-Glu-Asp-Gly), which is a different compound again
- Kimera sells it as "Brochogen", a spelling that returns nothing in the literature; their own description and image file say Bronchogen